Trevi Q1 net loss widens to $13.2 million; cash runway extended into 2030
Trevi Therapeutics reported a first-quarter 2026 net loss of $13.2 million, up from $10.3 million a year earlier, as research and development and general and administrative expenses rose. The company said an April 2026 common stock offering, with net proceeds of about $162 million, extends its expected cash runway into 2030, and it reiterated plans to start Phase 3 trials in IPF-related chronic cough.
Key points
- Net loss of $13.2 million for the quarter ended March 31, 2026, versus $10.3 million in the same period of 2025
- R&D expenses rose to $9.9 million from $7.8 million; G&A expenses rose to $5.0 million from $3.7 million
- Net proceeds of about $162 million from the underwritten common stock offering completed in April 2026
- Cash, cash equivalents and marketable securities were $171.8 million at March 31, 2026; first Phase 3 trial expected to start in the second quarter of 2026
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.